Breast-implant removal: implant-only, partial, total, and “en bloc” capsulectomy are not synonyms

Breast-implant removal and capsulectomy are separate operative choices. Implant-only removal takes out the device while leaving some or all capsule; partial capsulectomy removes part of the capsule; total capsulectomy removes the complete capsule, not necessarily in one piece; total intact capsulectomy removes it as one unit. The Breast Surgery Collaborative Community defines “en bloc” as removal of the capsule with a margin of uninvolved tissue for suspected or established implant-associated cancer after appropriate workup—not as a routine synonym for total intact removal.¹²

The operation should follow the indication, imaging and pathology question, implant and capsule anatomy, surgical risk, and reconstruction goal. A dramatic label cannot settle those variables.

Use the consensus terms literally

Ask the surgeon to place the proposed term in the consent and operative estimate. “En bloc when possible” can conceal whether the actual plan is total intact, total, partial, or conversion based on safety.

The indication should drive capsule extent

Possible reasons for surgery include device rupture or deflation, capsular contracture, malposition, infection, pain, asymmetry, implant exposure, a capsule abnormality, a change in reconstruction, patient preference, systemic symptoms under evaluation, or suspected implant-associated cancer. These are not one disease.

The BSCC statement identifies possible capsulectomy indications such as capsular contracture, rupture, or capsule abnormality and says risk and benefit should be considered through shared decision-making.¹ It also says it is unknown whether capsulectomy prevents future implant-associated cancer and that monitoring remains relevant after surgery.

For a cancer concern, diagnostic workup can change the operation. Fluid, mass, capsule, imaging, and pathology handling need coordination before tissue is disrupted.

Implant records come before the operation map

Retrieve:

• original operative report;
• manufacturer device card;
• implant manufacturer, model or style, size, fill, shell surface, and serial or lot;
• placement plane and incision;
• later revision records;
• imaging and reports;
• symptoms and examination;
• any aspiration, cytology, biopsy, or pathology; and
• recall or safety-communication match.

FDA states that implants are not lifetime devices and that complications and future operations become more likely over time.³⁴ A missing device card does not prove the implant type; request records from the surgeon, facility, and manufacturer tracking system when available.

“All capsule” can collide with anatomy

Capsule may be adherent to the chest wall, ribs, muscle, or other tissue, and prior surgery can alter planes. Removing more tissue may increase operative dissection and can change bleeding, pneumothorax, contour, reconstruction, and anesthesia considerations. The risk depends on location and individual anatomy.

Ask the surgeon to draw:

1. implant pocket and plane;
2. capsule regions;
3. abnormal fluid or mass;
4. intended capsule removal;
5. any planned uninvolved-tissue margin;
6. structures that may limit safe removal;
7. conversion conditions; and
8. reconstruction after removal.

A safety-driven change during surgery should have a preoperative consent and documentation pathway.

Pathology is not one generic test

Routine gross examination, histology, cytology of fluid, immunohistochemistry, culture, and other testing answer different questions. Ask what specimen exists, what clinical concern drives testing, how it is oriented and labeled, and who communicates the result.

Do not assume a photograph of an intact capsule is a pathology result or proof that every capsule cell was removed.

Removal does not choose the new breast shape

After explant, options may include no replacement, implant exchange, lift, fat grafting, flap reconstruction, tissue expansion, or staged work. Each adds its own goals, scars, device or graft records, and revision horizon.

The breast-lift-versus-implant guide separates tissue repositioning from added device volume. Ask what the breast is expected to look like after removal alone before adding another operation.

Price every operative component

The estimate should separate surgeon, facility, anesthesia, implant removal, capsule work, pathology, new implant or reconstruction, garments, medicines, follow-up, imaging, complication care, and possible overnight care. “Explant package” may not include pathology or an unplanned conversion.

Use the good-faith-estimate guide to identify every provider. A device warranty may cover replacement product without covering removal, capsule surgery, facility, or anesthesia.

Choose the narrowest accurate operation name

1. Recover the device history. Collect implant card, operative reports, model and surface, plane, revisions, imaging, symptoms, and prior pathology.
2. State the indication. Separate preference, contracture, rupture, malposition, infection, symptoms, capsule abnormality, and suspected cancer.
3. Use consensus terminology. Write implant-only, partial, total, total intact, or cancer-indicated en bloc scope without treating the words as upgrades.
4. Map anatomical limits. Identify capsule regions, adherent structures, abnormal findings, intended margin, conversion triggers, and reconstruction.
5. Preplan specimens. Assign fluid, mass, capsule, implant, culture, cytology, and pathology handling plus result ownership.
6. Reconcile the final record. Compare consent with the operative report, specimen list, photographs, pathology, invoice, and ongoing surveillance plan.

The decisive question is: “What diagnosis or surgical objective requires this exact amount of capsule removal, and is the proposed term describing the real anatomy, specimen plan, and risk rather than a marketing hierarchy?”